News
A
132.44
-1.57%
-2.11
Press Release: Reitmans (Canada) Limited Reports Fiscal 2024 and Fourth Quarter Fiscal 2024 Financial Results
Reitmans (Canada) Limited Reports Fiscal 2024 and Fourth Quarter Fiscal 2024 Financial Results. Net revenues were $794.7 million for the fourth quarter of fiscal 2024. Reitmans is Canada's leading specialty apparel retailer. The Company is pleased with the results for the year.
Dow Jones · 20h ago
Press Release: Reitmans (Canada) Limited Reports -2-
This press announcement indicates Adjusted EBITDA as a percentage of net revenues and is considered a non-GAAP financial ratio. The intent of presenting adjusted earnings before interest, taxes, depreciation and amortization and adjusted results from operating activities is to provide additional useful information to investors and analysts. Adjusted ROA is defined as results of operating activities excluding Federal subsidies and other items.
Dow Jones · 20h ago
Notable ETF Outflow Detected - SPXL, MMM, AES, A
NASDAQ · 1d ago
PacBio cut to Neutral at Goldman Sachs after guidance cut
Goldman Sachs downgraded its recommendation on PacBio to Neutral from Buy. The gene sequencing company lowered its full-year guidance below consensus with its preliminary Q1 results. PacBio cut to Neutral at Goldman Sachs after guidance cut. Analyst Matthew Sykes lowered his rating on the California-based company to Neutral.
Seeking Alpha · 1d ago
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)
TipRanks · 2d ago
AGILENT TECHNOLOGIES INC <A.N>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $145 FROM $141
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 2d ago
BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates
Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln. Analysts point to weakness in JNJ's vision care products and surgical devices. Stryker, Zimmer Biomet and Medtronic among those down.
Reuters · 3d ago
Here's How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years
Agilent Technologies has outperformed the market over the past 10 years by 3.06% on an annualized basis. The company has an average annual return of 13.59%. Agilent has a market capitalization of $41.24 billion. If an investor bought $100 of A stock 10 years ago, it would be worth $359.36 today.
Benzinga · 4d ago
AGILENT RECEIVES EUROPEAN IVDR CLASS C CERTIFICATION FOR GENETISURE DX POSTNATAL ASSAY
Reuters · 4d ago
Weekly Report: what happened at A last week (0408-0412)?
Weekly Report · 4d ago
U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map
As of April 11, there were 158 U.S. Wide-moat stocks meeting Morningstar's criteria. Only 4.4% of these stocks earned a 5-star valuation rating. The heat map of the most investable candidates lists the best companies on sale. We focus on the most attractively valued stocks with a wide- moat rating.
Seeking Alpha · 04/12 09:11
Agilent Is Maintained at Underweight by Barclays
Dow Jones · 04/10 19:46
Barclays Maintains Underweight on Agilent Technologies, Raises Price Target to $135
Benzinga · 04/10 19:36
908 Devices: Rare Early-Stage Bioprocess Investment Opportunity
908 Devices, Inc. Is a company focused on mass spectrometry and bioprocessing 4.0. The company has three main platforms for growth in the forensic industry. Life science tools are essential for the growth of the healthcare industry. 908 Devices is a rare early-stage investment opportunity in the life science tools industry.
Seeking Alpha · 04/10 16:49
(A) - Analyzing Agilent Technologies's Short Interest
Agilent Technologies's short percent of float has risen 31.43% since its last report. The company has 3.58 million shares sold short, which is 1.38% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/10 15:00
Agilent Technologies Reaches Analyst Target Price
NASDAQ · 04/10 14:54
Barclays Reaffirms Their Sell Rating on Agilent (A)
TipRanks · 04/10 06:46
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Illumina CFO Joydeep Goswami to depart, former Summit Therapeutics exec Ankur Dhingra to succeed. Gene sequencing company Illumina says he will be succeeded by former Summit executive. Company has reaffirmed its forecast for the first quarter and full-year 2024.
Reuters · 04/09 21:28
Transcenta, Agilent To Develop CLDN18.2 Companion Diagnostic To Support Osemitamab Phase III Trial
NASDAQ · 04/09 01:22
More
Webull provides a variety of real-time A stock news. You can receive the latest news about Agilent Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About A
Agilent Technologies, Inc. is engaged in providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets segment provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Agilent CrossLab segment offers services portfolio, which includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the laboratory operations.